Ad copy

Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and in diverse clinical settings across the US, investigations have found. The phenomenon of such easy access to a drug that’s not approved anywhere for any indication is arguably without precedent. Patients are discovering the drug — a GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon agonist — through social media, purchasing it from vendors online, and arriving at clinic appointments either asking about it or disclosing they are already using it. News reports state that everyone from “shadowy online vendors” to physicians and nurses is illegally promoting the drug before it receives the FDA approval. Tap the link in our bio to read the full story.